secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0000950170-24-030505
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen receives FDA orphan drug and rare pediatric disease designations for DMD candidate PGN-EDO51
--------------------------------------------------------------------------------

- FDA granted orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapy for DMD.
- PGN-EDO51 targets DMD patients whose mutations are amenable to exon 51 skipping approach.
- Ongoing CONNECT1 Phase 2 trial; CONNECT2 Phase 2 enrollment expected later in 2024.
- Orphan designation offers 7-year U.S. exclusivity plus tax credits and fee benefits upon approval.
- Rare pediatric disease designation may yield a priority review voucher for a future product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024030505/0000950170-24-030505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024030505/pepg-20240313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-030505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer